Compare NAN & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAN | TENX |
|---|---|---|
| Founded | 1999 | 1967 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.4M | 317.8M |
| IPO Year | N/A | 2001 |
| Metric | NAN | TENX |
|---|---|---|
| Price | $11.26 | $12.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 78.2K | ★ 630.5K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.79 | $5.34 |
| 52 Week High | $11.67 | $18.38 |
| Indicator | NAN | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 38.61 | 43.34 |
| Support Level | $11.12 | $10.83 |
| Resistance Level | $11.60 | $14.15 |
| Average True Range (ATR) | 0.07 | 0.73 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 5.58 | 44.59 |
Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.